TH-Z145, a lipophilic bisphosphonate, is a FPPS inhibitor (IC50: 210 nM)[1].
TH-Z145 (20 μg, i.p.) exhibits strong proplactic effects in a pathogenic influenza model[1].
| Animal Model: | B16-OVA cells (s.c.) xenograft mice model[1]. |
| Dosage: | 20 μg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited tumor growth and prolonged survival. |
[1]. Xia Y, et al. The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. Cell. 2018 Nov 1;175(4):1059-1073.e21.